Rani Therapeutics
Update in progressRANI (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company developing oral delivery of biologics and drugs to replace injections. Its RaniPill capsule is a drug-agnostic oral platform for oligonucleotides, peptides, proteins, and antibodies. Pipeline includes RT‑105 (preclinical anti-TNF‑alpha for RA), RT‑116 (obesity), RT‑117 (rare diseases), RT‑111 (ustekinumab biosimilar). Collaborations: ProGen for RT‑114 obesity and Chugai for an oral hemophilia program. Founded 2012; based in San Jose, California.
Company score
- Sentiment
- 0.43
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.20
- Governance
- 0.12
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.26
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!